Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: Neuropharmacology. 2009 Feb 5;56(0):10.1016/j.neuropharm.2009.01.020. doi: 10.1016/j.neuropharm.2009.01.020

Figure 5. The effect of varying the pre-administration time of PG01037 on the mean L-dopa-dependent AIM scores.

Figure 5

(A) The effect of varying the pretreatment time for PG01037 (10 mg/kg) prior to L-dopa administration (8 mg/kg L-dopa and benserazide) on both the total AIMs score (solid bars) and the AIMs score minus the locomotor component (hatched bars) is shown. Values are expressed as the percent of the corresponding vehicle control values. The bar graph corresponds to the following values for the mean ± S.E.M. normalized total AIM scores and the AIM scores minus the locomotor component, respectively: a) 60 minutes pretreatment, 65.9% ± 2.7 and 64.4% ± 2.9 with n = 9, b) 30 minutes pretreatment, 51.3% ± 5.7 and 51.2% ± 4.8 with n = 8 and c) 0 minutes pretreatment, 42.4% ± 7.0 and 44.2% ± 7.0 with n = 10. PG01037 statistically decreased the abnormal involuntary movements (p < 0.0001) at all time points. (B) The variation in the total AIMs score as a function of time is shown using zero time pretreatment with 10 mg/kg PG01037 (●) or vehicle control (○). Animals were also injected (i.p.) with 8 mg/kg L-dopa and benserazide. Each point is the summation of total AIM scores for 11 animals at each observation time point. This represents a mean 59.0 ± 21.8 (S.E.M.) percent reduction in the total AIMs score over the observation time. Plots of the summation of the AIMs score minus the locomotor component are essentially identical in shape with a 56.9 ± 22.3 percent reduction in the AIMs minus locomotor component.